Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs

Yang, Wenying; ERSOY, CANAN; Wang, Guixia; Ye, Shandong; Liu, Jun; Miao, Heng; Asirvatham, Arthur; Werther, Shanti; Kadu, Priti; Chow, Francis

doi:10.1016/j.diabres.2019.02.023

Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs

Atıf İçin Kopyala

Yang W., ERSOY C., Wang G., Ye S., Liu J., Miao H., ...Daha Fazla

DIABETES RESEARCH AND CLINICAL PRACTICE, cilt.150, ss.158-166, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 150
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.diabres.2019.02.023
Dergi Adı: DIABETES RESEARCH AND CLINICAL PRACTICE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.158-166
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Aims: To compare the efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) administered three times daily (TID) vs. twice daily (BID), plus metformin, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin +/- 1 oral antidiabetic drug (OAD).